Welcome to our dedicated page for Oncotelic Therapeutics news (Ticker: OTLC), a resource for investors and traders seeking the latest updates and insights on Oncotelic Therapeutics stock.
Oncotelic Therapeutics, Inc. (OTCQB: OTLC) generates a diverse stream of news centered on oncology, rare pediatric cancers, RNA-based therapeutics, AI-driven discovery, and nanomedicine. As a clinical-stage biopharmaceutical company, it regularly reports on scientific publications, joint venture progress, platform launches, and financing developments that shape its pipeline and corporate strategy.
Investors and researchers following OTLC news will encounter updates on key assets such as OT-101, a TGFB2 antisense agent associated with rare pediatric designation for DIPG through joint venture GMP Bio, and Sapu003, an intravenous Deciparticle formulation of everolimus developed by 45% owned JV Sapu Nano. Press releases highlight biomarker frameworks for identifying tumors likely to respond to Sapu003, pharmacokinetic data showing reduced gastrointestinal accumulation compared with oral everolimus, and broader Deciparticle platform data demonstrating formulation of multiple hydrophobic drug classes.
Oncotelic’s news flow also covers its PDAOAI evidence-interrogation platform, including open access for researchers to a TGF-β knowledge corpus of more than 125,000 PubMed abstracts via a dedicated Discord channel. Additional announcements describe peer-reviewed publications on context-dependent biomarkers in liver and pancreatic cancer, sub-15 nm nanoparticles for drug delivery, and survival-associated biological axes such as TGFB2, DNMT3A, and GMPS.
From a corporate and capital markets perspective, OTLC news includes independent valuations of its joint venture GMP Bio pipeline, potential fair-value remeasurements under U.S. GAAP, and registration statements related to equity purchase and note agreements with institutional investors. Regularly reviewing this news page allows readers to track how scientific advances, joint venture activities, AI platforms, and financing structures intersect within Oncotelic’s evolving oncology and rare disease portfolio.
Oncotelic Therapeutics (OTLC) has appointed Dr. Fatih Uckun as Chief Medical Officer, enhancing its leadership at a pivotal time for the company. Dr. Uckun, a veteran in oncology with over 30 years of experience, will oversee the execution of crucial registrational trials for OT-101, aimed at treating difficult cancers such as DIPG and pancreatic cancer. His extensive background includes significant achievements in immunotherapy research. The company recently completed a joint venture for OT-101, which has shown promise in previous clinical trials, including positive outcomes in treating COVID-19.
Oncotelic Therapeutics, Inc. (OTCQB:OTLC) announced its financial results for FY 2021, revealing a net loss of approximately $10.5 million, compared to a $10 million loss in FY 2020. The company reported no service revenue in FY 2021, a decline from $1.7 million in FY 2020. Research and development expenses decreased to $3.7 million, while general and administrative costs increased to $5.5 million. The company formed a joint venture with Dragon Overseas, expected to reduce future expenses, and anticipates significant operational changes in FY 2022, focusing on new drug developments and potential uplisting to a national stock exchange.
Oncotelic Therapeutics (OTCQB:OTLC) has formed a joint venture with Dragon Overseas Capital to develop TGF-β therapeutics, particularly focusing on the drug OT-101. This candidate targets pediatric brain cancer (DIPG) and shows promising safety and efficacy results. The JV will handle drug development costs, while Oncotelic anticipates financial benefits from a potential $50 million sale of a Rare Pediatric Disease voucher. Future clinical trials are planned, aiming for an IPO, bolstered by strong backing from Dragon Overseas, which is investing approximately $27.6 million for a majority stake.
Oncotelic Therapeutics (OTLC) has announced a Joint Venture (JV) with Dragon Overseas Capital Limited for the development of TGF-β therapeutics. This agreement will relieve Oncotelic of high drug development costs while allowing it to participate in the JV's financial upside. The JV will focus on OT-101, which has shown promise in clinical trials for conditions like DIPG and pancreatic cancer. Dragon Overseas will invest approximately $27.6 million for a 55% stake in the JV, while Oncotelic licenses OT-101 for a 45% ownership. The JV is headquartered in Hong Kong.
Oncotelic Therapeutics (OTCQB:OTLC) recently announced its plans to present studies on its TGF-β program at the AACR Annual Meeting 2022, highlighting the correlation between TGF-β expression and immune evasion in cancer and COVID-19.
The company's lead product, OT-101, has shown efficacy in over six clinical trials for solid tumors and a completed phase 2 trial against COVID-19. OT-101 is currently involved in a phase 1b trial combined with IL-2 and several upcoming trials with pembrolizumab.
Oncotelic Therapeutics, Inc. (OTCQB:OTLC) announced that Dr. Anthony E. Maida, Chief Clinical Officer, will present at the Evolution Summit in Los Angeles. Dr. Maida, an expert in immunotherapy, will discuss becoming truly patient-centric in healthcare. His career includes leading clinical research and raising over USD 200 million for biotech firms. Oncotelic focuses on developing TGF-β immunotherapies for late-stage cancers and has a promising drug candidate, OT-101. The company also acquired AL-101 for treating Parkinson's disease and erectile dysfunction.
Oncotelic Therapeutics (OTLC) announced Dr. Vuong Trieu's presentation at the MedInvest Pharmaceuticals and Biotechnology Investor Conference from March 28 - April 1, 2022. The company aims to reveal a Joint Venture with Golden Mountain Partners, which will focus on drug development and a new manufacturing facility. Oncotelic's lead drug, OT-101, has shown promising results in various clinical trials, including efficacy against solid tumors and COVID-19. The JV aims to secure funding for advancing Oncotelic's portfolio towards market approval.
Oncotelic Therapeutics (OTLC) is advancing its lead candidate, OT-101, an RNA therapeutic targeting TGF-β, having completed over six clinical trials demonstrating good efficacy against solid tumors. OT-101 is currently in a phase 1b trial combined with IL-2, with additional trials using pembrolizumab in development. The company is preparing to announce a joint venture with Golden Mountain Partners at the upcoming MedInvest Conference. This partnership aims to bolster Oncotelic's oncology drug portfolio and secure funding for future developments.
Oncotelic Therapeutics (OTLC) announced the development of OT-101, its RNA therapeutic targeting TGF-β, which has shown good efficacy in over six clinical trials against solid tumors. Currently, OT-101 is in a phase 1b trial combined with IL-2 and is being tested alongside pembrolizumab in multiple trials. The company is set to present its immunotherapy pipeline at BiotechGate Digital Partnering from Feb 7-11, 2022, aiming for transformative outcomes in treating high-TGF solid tumors. OT-101 has also shown efficacy against COVID-19 in a completed phase 2 trial.
Oncotelic Therapeutics (OTCQB:OTLC) has submitted a clinical study protocol to the US FDA for a Phase 1 trial of CA4P combined with pembrolizumab for melanoma treatment. This multicenter, open-label study aims to assess the safety and initial efficacy of CA4P in patients with recurrent metastatic melanoma. CA4P has been previously evaluated in over 500 patients across 17 studies. The trial leverages CA4P's potential synergy with checkpoint inhibitors and seeks to gain marketing approval for CA4P in a Rare Pediatric Disease.